NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research

        • Research Overview
        • Clinical Research Facility
        • 15 Research Themes

        • Cancer
        • Cardiovascular Medicine
        • Digital Health from Hospital to Home
        • Gene and Cell Therapy
        • Genomic Medicine
        • Imaging
        • Inflammation across Tissues
        • Life-saving Vaccines
        • Metabolic Experimental Medicine
        • Modernising Medical Microbiology and Big Infection Diagnostics
        • Musculoskeletal
        • Preventive Neurology
        • Respiratory Medicine
        • Surgical Innovation, Technology and Evaluation
        • Translational Data Science
  • Patient & Public Involvement
    • Getting involved with research
    • Welcome Guide
    • View and register for involvement opportunities
    • Patient & Public Groups
    • Patient and Public Involvement Advisory Group
    • Diversity in Research Group
    • Case Studies
    • Patient and Public Involvement and Engagement (PPIE) Strategy
    • PPIE News
    • PPI Researcher Guidance
    • Researchers: Post a PPIE opportunity
    • Public events
    • Patient & Public Involvement events
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Preparatory Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • Who Do We Work With?
    • Events
    • Further Information and Additional Resources
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > Translational Data Science > New clinical prediction tools for myeloma developed

New clinical prediction tools for myeloma developed

9 April 2021 · Listed under Cancer, Translational Data Science

University of Oxford researchers have developed new clinical prediction models for use in primary care with the aim of accelerating the diagnosis of myeloma, a cancer of the bone marrow.

Histopathological image of multiple myoloma
(Photo: wikimedia commons)

Myeloma caused 117,077 deaths worldwide in 2020. Earlier diagnosis improves the rate of survival but unfortunately, delays in myeloma diagnosis are common and result in poorer patient outcomes.

One reason for these delays is that myeloma symptoms are non-specific and relatively common in people without cancer. For example, back pain is associated with myeloma, yet there are many other non-myeloma causes of this symptom.

Additional measures are therefore needed to highlight the possibility of myeloma in patients where GPs do not initially suspect this disease. GPs frequently order simple laboratory tests, such as the full blood count, to investigate patients presenting with non-specific symptoms.

Previous research by Dr Constantinos Koshiaris, Dr Jason Oke, Dr Brian Nicholson and colleagues from the University of Oxford’s Nuffield Department of Primary Care Health Sciences and the University of Exeter identified certain abnormalities in blood test results that indicate a higher risk of myeloma, such as low haemoglobin which can be observed up to two years before a myeloma diagnosis.

In their latest paper, published in the British Journal of General Practice, this research team, a number of whose members are supported by the NIHR Oxford Biomedical Research Centre, have developed new clinical prediction models for myeloma that incorporate both symptoms and blood test results.

Using the Clinical Practice Research Datalink (GOLD version), a primary care database containing electronic health records for more than 11 million patients in the UK, the team identified the most common symptoms and full blood count results recorded for patients with myeloma.

The most predictive of these were included in the models they developed and the new tools were validated against a set of test data. Decisions made using their prediction models resulted in fewer false positives and more true positives when compared to single tests or symptoms alone.

By identifying patients at highest risk of myeloma in primary care, these new prediction rules have the potential to reduce diagnostic delays by a substantial amount.

Further research is now needed to understand more about the feasibility and implementation of this tool in the primary care setting and the impact it will have on the diagnostic pathway and patient outcomes.

← Risk of severe COVID-19 from asthma and other respiratory diseases may be only modestly increased, new analysis suggests
National survey reveals big reductions in COVID-19 infections with single dose of Oxford-AZ and Pfizer vaccines →

Other news

News Categories

News by Month

See all news

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2023 NIHR Oxford Biomedical Research Centre